ADGI [NASD]
Adagio Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.08 Insider Own24.30% Shs Outstand107.87M Perf Week-11.19%
Market Cap289.43M Forward P/E- EPS next Y-1.50 Insider Trans0.00% Shs Float73.99M Perf Month-9.03%
Income-288.80M PEG- EPS next Q-0.57 Inst Own68.40% Short Float5.28% Perf Quarter-58.68%
Sales- P/S- EPS this Y-784.00% Inst Trans0.86% Short Ratio1.22 Perf Half Y-85.78%
Book/sh4.26 P/B0.62 EPS next Y49.00% ROA-51.10% Target Price3.83 Perf Year-
Cash/sh4.82 P/C0.54 EPS next 5Y- ROE-76.70% 52W Range2.46 - 78.82 Perf YTD-63.91%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-96.68% Beta-
Dividend %- Quick Ratio5.80 Sales past 5Y- Gross Margin- 52W Low6.50% ATR0.25
Employees101 Current Ratio5.80 Sales Q/Q- Oper. Margin- RSI (14)36.71 Volatility8.65% 9.02%
OptionableYes Debt/Eq0.00 EPS Q/Q-161.70% Profit Margin- Rel Volume0.33 Prev Close2.63
ShortableYes LT Debt/Eq0.00 EarningsMay 13 BMO Payout- Avg Volume3.20M Price2.62
Recom3.20 SMA20-8.72% SMA50-25.92% SMA200-85.30% Volume1,066,108 Change-0.38%
Jan-06-22Downgrade Morgan Stanley Overweight → Underweight
Dec-22-21Downgrade Jefferies Buy → Hold $46 → $10
Dec-15-21Downgrade Stifel Buy → Hold $50 → $9
Dec-15-21Downgrade Guggenheim Buy → Neutral
Nov-29-21Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $49
Aug-31-21Initiated Stifel Buy $57
Aug-31-21Initiated Morgan Stanley Equal-Weight $33
Aug-31-21Initiated Jefferies Buy $60
Aug-31-21Initiated Guggenheim Buy $40
May-13-22 06:30AM  
Apr-14-22 07:45AM  
Apr-07-22 12:09PM  
Mar-31-22 12:14PM  
06:00AM  
Mar-30-22 10:50AM  
10:39AM  
09:33AM  
08:34AM  
08:24AM  
06:30AM  
Mar-24-22 06:22AM  
Mar-23-22 06:32PM  
Mar-18-22 06:33PM  
Feb-23-22 04:30PM  
Feb-22-22 02:21PM  
01:08PM  
07:30AM  
Feb-18-22 07:33PM  
Feb-03-22 04:35PM  
Jan-20-22 05:05PM  
Jan-13-22 07:08AM  
Jan-12-22 04:57PM  
Jan-06-22 06:30AM  
Dec-29-21 05:30AM  
Dec-24-21 12:38AM  
Dec-22-21 07:17PM  
11:11AM  
08:21AM  
Dec-21-21 01:38AM  
Dec-18-21 12:38AM  
Dec-17-21 08:00AM  
Dec-16-21 11:38PM  
04:13PM  
02:38PM  
07:54AM  
Dec-15-21 01:50PM  
10:24AM  
Dec-14-21 04:11PM  
12:41PM  
12:39PM  
11:16AM  
10:56AM  
07:00AM  
06:51AM  
Dec-11-21 05:38AM  
Dec-09-21 08:38AM  
Dec-08-21 03:16PM  
05:57AM  
Dec-07-21 10:15AM  
Dec-04-21 07:52AM  
Dec-03-21 12:34PM  
Dec-02-21 08:38AM  
Nov-30-21 04:15PM  
12:00PM  
09:37AM  
08:59AM  
08:00AM  
Nov-29-21 02:16PM  
01:05PM  
01:01PM  
06:39AM  
06:30AM  
Nov-22-21 06:30AM  
Nov-15-21 06:30AM  
Nov-10-21 06:30AM  
Nov-06-21 08:10AM  
Oct-19-21 08:31AM  
06:30AM  
Oct-04-21 10:54AM  
05:20AM  
Oct-01-21 12:41PM  
Sep-29-21 09:33AM  
06:30AM  
06:30AM  
Aug-10-21 04:22PM  
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.